DRG Epidemiology’s coverage of myelofibrosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of myelofibrosis for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

DRG Epidemiology’s myelofibrosis forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with myelofibrosis per year?
  • Of all people diagnosed with myelofibrosis, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of myelofibrosis over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following myelofibrosis subpopulations:

  • Diagnosed incident cases of primary myelofibrosis.
  • Diagnosed incident cases of secondary myelofibrosis.
  • Diagnosed prevalent cases of primary myelofibrosis.
  • Diagnosed prevalent cases of secondary myelofibrosis.
  • Diagnosed incident cases of primary myelofibrosis by biomarker status and comorbidity.
  • Diagnosed incident cases of myelofibrosis by International Prognostic Scoring System.
  • Diagnosed prevalent cases of myelofibrosis by Dynamic International Prognostic Scoring System.
  • Diagnosed incident cases of secondary myelofibrosis by the myelofibrosis secondary to polycythemia vera and essential thrombocythemia prognostic model.
  • Diagnosed prevalent cases by treatment status.

Note: Coverage may vary by country.

Table of contents

  • Mature Markets
    • Introduction
      • Key Updates
      • Diagnosed Incidence of Myelofibrosis per 100,000 People of All Ages in 2018 and 2038
      • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Myelofibrosis over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases of Myelofibrosis
      • Diagnosed Prevalent Cases of Myelofibrosis
      • Diagnosed Incident Cases of Myelofibrosis by IPSS
      • Diagnosed Prevalent Cases of Myelofibrosis by DIPSS
      • Diagnosed Incident Cases of Primary Myelofibrosis by Comorbidity
      • Diagnosed Prevalent Cases of Primary Myelofibrosis by Comorbidity
      • Diagnosed Incident Cases of Primary Myelofibrosis by Biomarker Status
      • Diagnosed Prevalent Cases of Primary Myelofibrosis by Biomarker Status
      • Diagnosed Incident Cases of Secondary Myelofibrosis by MYSEC-PM
      • Drug-Treated Prevalent Cases of Myelofibrosis
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Narendra Parihar

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.


Related Reports

Myelofibrosis | Landscape & Forecast | Disease Landscape & Forecast

Myelofibrosis is a hematological malignancy characterized by disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and splenomegaly. Inc...

View Details